Stocktwits on MSN
ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon
Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. ・The ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial ESTERO, FL / / January 7, 2026 / Aspire Biopharma Holdings ...
Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201 ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical ...
The first sublingual therapy for the intermittent treatment of uncontrolled OFF episodes for adult people living with Parkinson’s Disease ...
SLIT vs SCIT: Which Immunotherapy Works Best for Children With Allergic Rhinitis? Review Sheds Light
A systematic review of randomized clinical trials suggests that both sublingual and subcutaneous allergen immunotherapy are effective options for managing allergic rhinitis ...
Objectives To review the metrics and findings of studies evaluating effects of drug decriminalisation or legal regulation on drug availability, use or related health and social harms globally. Design ...
When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.
Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-YearNEW YORK, Dec. 22, 2025 (GLOBE ...
The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback